Pharmacological characterization of RWJ-676070, a dual vasopressin V1A/V2 receptor antagonist-Reference-Cited by-同舟云学术

Pharmacological characterization of RWJ-676070, a dual vasopressin V1A/V2 receptor antagonist

Published:2008-08 Issue:1-3 Volume:590 Page:333-342
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Gunnet Joseph W.,Wines Pamela,Xiang Min,Rybczynski Philip,Andrade-Gordon Patricia,de Garavilla Lawrence,Parry Tom J.,Cheung Wai-man,Minor Lisa,Demarest Keith T.,Maryanoff Bruce E.,Damiano Bruce P.

Publisher

Elsevier BV

Subject

Pharmacology

Reference52 articles.

1. Therapeutic potential of vasopressin receptor antagonists;Ali;Drugs,2007

2. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin;Anderson;Ann. Intern. Med.,1985

3. Vasopressin receptor antagonists: potential indications and clinical results;Arai;Curr. Opin. Pharmacol.,2007

4. Role of vasopressin in essential hypertension: racial differences;Bakris;J. Hypertens.,1997

5. Vasopressin and diabetes mellitus;Bankir;Nephron,2001

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaptans or voluntary increased hydration to protect the kidney: how do they compare?;Nephrology Dialysis Transplantation;2021-09-29

2. Excessive maternal salt intake gives rise to vasopressin-dependent salt sensitivity of blood pressure in male offspring;Journal of Molecular and Cellular Cardiology;2021-01

3. Increased activity of the orexin system in the paraventricular nucleus contributes to salt-sensitive hypertension;American Journal of Physiology-Heart and Circulatory Physiology;2017-12-01

4. Brain Gαi2-subunit proteins and the prevention of salt sensitive hypertension;Frontiers in Physiology;2015-08-19

5. In vitro and in vivo pharmacological characterisation of the potent and selective vasopressin V1A receptor antagonist 4-[4-(4-Chloro-phenyl)-5-[1,2,3]triazol-2-ylmethyl-4H-[1,2,4]triazol-3-yl]-piperidin-1-yl-(3,5-difluoro-phenyl) methanone (PF-00738245);European Journal of Pharmacology;2011-11